FLT3 and acute myeloid leukemia: Sorafenib was studied in another randomized trial, a phase III study of 202 adult patients with FLT3-ITD+ AML who received alloHSCT and had hematopoietic recovery within day +60 who were randomized to sorafenib or non-maintenance control at 30-60 days post-alloHSCT (94).